MARKET

PLRX

PLRX

Pliant Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.17
-0.59
-2.29%
Closed 16:00 07/10 EDT
OPEN
25.51
PREV CLOSE
25.76
HIGH
25.74
LOW
24.75
VOLUME
60.66K
TURNOVER
--
52 WEEK HIGH
35.63
52 WEEK LOW
21.05
MARKET CAP
861.90M
P/E (TTM)
101.12
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PLRX stock price target is 43.33 with a high estimate of 50.00 and a low estimate of 40.00.

EPS

PLRX News

More
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29)
Benzinga · 06/30 11:41
Needham Initiates Coverage On Pliant Therapeutics with Buy Rating, Announces Price Target of $40
Needham analyst Alan Carr initiates coverage on Pliant Therapeutics (NASDAQ:PLRX) with a Buy rating and announces Price Target of $40.
Benzinga · 06/29 12:59
Cowen & Co. Initiates Coverage On Pliant Therapeutics with Outperform Rating
Cowen & Co. analyst Ritu Baral initiates coverage on Pliant Therapeutics (NASDAQ:PLRX) with a Outperform rating.
Benzinga · 06/29 11:45
Citigroup Initiates Coverage On Pliant Therapeutics with Buy Rating, Announces Price Target of $40
Citigroup analyst Joel Beatty initiates coverage on Pliant Therapeutics (NASDAQ:PLRX) with a Buy rating and announces Price Target of $40.
Benzinga · 06/29 11:44
Piper Sandler Initiates Coverage On Pliant Therapeutics with Overweight Rating, Announces Price Target of $50
Piper Sandler analyst Tyler Van Buren initiates coverage on Pliant Therapeutics (NASDAQ:PLRX) with a Overweight rating and announces Price Target of $50.
Benzinga · 06/29 11:42
The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week
Biotech stocks went on a seesaw ride along with the broader markets in the week ended June 26. Yet there were some encouraging developments on the COVID-19 vaccine development front. Vaccine companies are going all out, forging alliances and adding personnel t
Benzinga · 06/28 18:25
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25)
Benzinga · 06/26 12:28
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24)
Benzinga · 06/25 12:26

Industry

Pharmaceuticals
-0.31%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About PLRX

Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis. It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-ß). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of avß6 and avß1. The Company’s second clinical-stage product candidate, PLN-1474, is a small-molecule, selective inhibitor of avß1 in development for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.
More

Webull offers kinds of Pliant Therapeutics Inc stock information, including NASDAQ:PLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PLRX stock methods without spending real money on the virtual paper trading platform.